Cargando…

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series

Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Assawasaksakul, Theerada, Sathitratanacheewin, Seelwan, Vichaiwattana, Preeyaporn, Wanlapakorn, Nasamon, Poovorawan, Yong, Kittanamongkolchai, Wonngarm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646968/
https://www.ncbi.nlm.nih.gov/pubmed/34862313
http://dx.doi.org/10.1136/rmdopen-2021-002019
_version_ 1784610528279134208
author Assawasaksakul, Theerada
Sathitratanacheewin, Seelwan
Vichaiwattana, Preeyaporn
Wanlapakorn, Nasamon
Poovorawan, Yong
Kittanamongkolchai, Wonngarm
author_facet Assawasaksakul, Theerada
Sathitratanacheewin, Seelwan
Vichaiwattana, Preeyaporn
Wanlapakorn, Nasamon
Poovorawan, Yong
Kittanamongkolchai, Wonngarm
author_sort Assawasaksakul, Theerada
collection PubMed
description Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications.
format Online
Article
Text
id pubmed-8646968
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86469682021-12-06 Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series Assawasaksakul, Theerada Sathitratanacheewin, Seelwan Vichaiwattana, Preeyaporn Wanlapakorn, Nasamon Poovorawan, Yong Kittanamongkolchai, Wonngarm RMD Open Lupus Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications. BMJ Publishing Group 2021-12-03 /pmc/articles/PMC8646968/ /pubmed/34862313 http://dx.doi.org/10.1136/rmdopen-2021-002019 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Lupus
Assawasaksakul, Theerada
Sathitratanacheewin, Seelwan
Vichaiwattana, Preeyaporn
Wanlapakorn, Nasamon
Poovorawan, Yong
Kittanamongkolchai, Wonngarm
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title_full Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title_fullStr Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title_full_unstemmed Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title_short Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
title_sort immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated sars-cov-2 vaccine in patients with sle: a case series
topic Lupus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646968/
https://www.ncbi.nlm.nih.gov/pubmed/34862313
http://dx.doi.org/10.1136/rmdopen-2021-002019
work_keys_str_mv AT assawasaksakultheerada immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries
AT sathitratanacheewinseelwan immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries
AT vichaiwattanapreeyaporn immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries
AT wanlapakornnasamon immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries
AT poovorawanyong immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries
AT kittanamongkolchaiwonngarm immunogenicitysafetyandreactogenicityofaheterogeneousboosterfollowingthecoronavacinactivatedsarscov2vaccineinpatientswithsleacaseseries